#Maipl Therapeutics #Endosure #MA-4604

Maipl Therapeutics Forms Strategic Alliance with Endosure

In a groundbreaking development within women's health, Maipl Therapeutics, Inc., a biopharmaceutical company specializing in non-hormonal therapies, has announced a strategic partnership with Endosure, Inc. This collaboration is set to significantly accelerate the first-in-human trials of a novel endometriosis therapy, known as MA-4604.

Endometriosis is a chronic condition affecting about one in ten women of reproductive age globally. Characterized by endometrial tissue growth outside the uterus, it causes significant pain and discomfort. Despite the prevalence of this disorder, the average diagnosis takes between eight to ten years, which can lead to severe complications such as infertility and organ damage. The economic burden for endometriosis in the USA alone tops $69.8 billion annually.

Innovative Diagnostics at the Forefront

The collaboration will utilize the ENDOSURE TEST, a revolutionary diagnostic tool developed by Endosure. This Tier-1 test offers a non-invasive, rapid, 30-minute assessment that can highly accurately diagnose endometriosis, regardless of its anatomical location. According to Dr. Yong Yue, CEO of Maipl Therapeutics, incorporating the ENDOSURE TEST into their clinical studies will streamline patient identification and enrollment, hence expediting the overall trial process.

“**Our alliance with Endosure allows us to leapfrog two of the greatest hurdles in endometriosis drug development—timely and accurate diagnosis and objective measurement of treatment effects,